

Published in final edited form as:

*Neurobiol Aging*. 2012 January ; 33(1): 195.e1–195.12. doi:10.1016/j.neurobiolaging.2010.05.008.

## **Ex vivo cultures of microglia from young and aged rodent brain reveal age-related changes in microglial function**

**eMalick G. Njie<sup>a,2,\*</sup>, Ellen Boelen<sup>b,c,1,2</sup>, Frank R. Stassen<sup>b</sup>, Harry W.M. Steinbusch<sup>c</sup>, David R. Borchelt<sup>a</sup>, and Wolfgang J. Streit<sup>a</sup>**

<sup>a</sup>Department of Neuroscience, University of Florida College of Medicine and McKnight Brain Institute, Gainesville, FL, United States <sup>b</sup>Department of Medical Microbiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht, the Netherlands

<sup>c</sup>Department of Neuroscience, FHML, School for Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, the Netherlands

### **Abstract**

To understand how microglial cell function may change with aging, various protocols have been developed to isolate microglia from the young and aged central nervous system (CNS). Here we report modification of an existing protocol that is marked by less debris contamination and improved yields and demonstrates that microglial functions are varied and dependent on age. Specifically, we found that microglia from aged mice constitutively secrete greater amounts of interleukin-6 (IL-6) and tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) relative to microglia from younger mice and are less responsive to stimulation. Also, microglia from aged mice have reduced glutathione levels and internalize less amyloid beta peptide (A $\beta$ ) while microglia from mice of all ages do not retain the amyloid beta peptide for a significant length of time. These studies offer further support for the idea that microglial cell function changes with aging. They suggest that microglial A $\beta$  phagocytosis results in A $\beta$  redistribution rather than biophysical degradation *in vivo* and thereby provide mechanistic insight to the lack of amyloid burden elimination by parenchymal microglia in aged adults and those suffering from Alzheimer's disease.

### **Keywords**

Microglia; Alzheimer's disease; Beta amyloid; Glutathione; Cytokine; IL-6; TNF- $\alpha$ ; Aging

## **1. Introduction**

A multitude of studies have implicated microglia as important players in the etiology of a number of age-related neurodegenerative diseases, including Alzheimer's disease (AD),

\*Corresponding author at: eMalick G. Njie, Department of Neuroscience, University of Florida College of Medicine, PO Box 100244, Gainesville, FL 32610-0244, United States. Tel.: +1 352 392 9596; fax.: +1 352 392 8347 email:emalick@ufl.edu(E.G. Njie).

<sup>1</sup>Present address: Biomedical Research Institute (BIOMED), Hasselt University, Diepenbeek, Belgium

<sup>2</sup>Both authors have contributed equally

### **Conflict of Interest**

None.

Parkinson's disease (PD) and amyotrophic lateral sclerosis (Boillee, et al., 2006, Chung, et al., 2001, El Khoury, et al., 2007, Frautschy, et al., 1998, Rogers, et al., 2002). While histological studies are essential in providing clues regarding the cells' involvement, they are limited in terms of evaluating the functions of living cells. In the past decade, protocols to isolate living microglia from postnatal animals have become available (Carson, et al., 1998, de Haas, et al., 2007, Frank, et al., 2006, Hickman, et al., 2008, Ponomarev, et al., 2005). These protocols either trap microglia using antibodies to cell-specific antigens (Hickman, et al., 2008, Tham, et al., 2003) or separate microglia using density centrifugation (de Haas, et al., 2007, Frank, et al., 2006). In both cases, the rapid isolation of microglia enables *ex vivo* experimentation of endogenous microglia in a controlled setting largely devoid of neurons, oligodendrocytes and astrocytes.

Protocols utilizing density centrifugation are advantageous to those utilizing antigen traps in terms of yield per brain (de Haas, et al., 2007). They also avoid artificial cellular reactions caused by antigen cross linking, a risk carried with the use of antibodies in trapping protocols. However, in our hands, significant amounts of non-microglial debris contaminate current density centrifugation derived cultures. In the present study, we sought to modify density centrifugation methodology to eliminate debris fields present in such cultures. With these modifications, microglial yields were preserved or slightly increased. These improvements allowed us to study microglial function and possible alterations during normal aging.

## 2. Material & Methods

### 2.1. Solutions

Dispace II (Roche, Mannheim, Germany) was reconstituted at 2U/mL in dispace buffer (0.9% HEPES, 50mM NaCl, pH 7.4) according to manufacturer's instructions. Percoll (GE Healthcare, St. Giles, UK) was diluted 1:10 with 10× phosphate-buffered saline (PBS) to create an isotonic solution. 1× PBS was added to isotonic percoll to create working solutions ranging from 75% to 25% percoll.

### 2.2. Animals

Debris reduction experiments were performed with non-transgenic C57BL/6 mice and mice expressing GFP under the fractalkine receptor promoter (Jung, et al., 2000). Experiments were performed using young (1–2 month old) and aged (14–16 month old) male C57BL/6 mice. The mice were housed at 22°C in a controlled 12hr light/dark cycle and provided food and water ad libitum. Animals were euthanized by exsanguination using transcardiac perfusion with PBS under deep anesthesia with sodium pentobarbital (50mg/kg body weight). This method of euthanasia is consistent with the recommendations of the Panel of Euthanasia of the American Veterinary Medical Association. After perfusion, the brain (telencephalon, cerebellum and midbrain) was rapidly removed.

### 2.3. Reduction of debris produced by brain homogenization

Each brain was washed in cold 1× PBS, then minced using small scissors. Brain tissue was gently dissociated by immersion into 10mLs (per brain) of dispace II solution (2U/mL),

trypsin solution (0.05%) or by grinding within a tissue homogenizer (glass Potter, Braun, Melsungen, Germany). Dissociated brain tissue was placed within a 50mL conical tube and laid horizontally in an orbital shaker set to shake for 1hr, 37°C at 150rpm. Remnant tissue chunks were further homogenized by rapidly triturating with a 10mL pipette (BD Biosciences, Boston, MA) with a wide bore to prevent cell shearing. This was carried out with a fully charged pipette aid (Drummond). Enzyme activity was halted by diluting the resultant homogenate 1:1 with cold 10% fetal bovine serum (FBS) in 1× PBS. Meninges and clumped cells were removed with 70µm filtration (BD Biosciences, Boston, MA) to obtain a suspension of single cells.

#### 2.4. Preparation of discontinuous percoll gradients

The homogenate was spun  $1000 \times g$  for 10min at 4°C. The supernatant was discarded and the pellet of an individual brain was resuspended in 6mLs of 75% isotonic percoll (high percoll) (GE Healthcare, Buckinghamshire, U.K.). Three mLs of this mixture was then aliquoted into a 15mL polystyrene tube. Five mLs of 35% isotonic percoll (low percoll) was layered atop the high concentration percoll at a rate of 150µl/sec to create a distinct interface between the percoll layers. To replicate gradients described in the literature, 25% percoll was utilized for low percoll. 1× PBS was layered atop the low concentration percoll. The resultant discontinuous gradient was then allowed to settle on ice for 15 minutes allowing most of the homogenate to naturally rise towards its isopycnic position. The gradient was then centrifuged at  $800 \times g$  for 45min in a HS-4 swinging bucket rotor (Thermo Fisher Scientific, Waltham, MA) set to 4°C. We did not notice changes in microglial yields with high acceleration or the application of the brake. However, yields were significantly diminished if the gradients are not processed immediately following centrifugation. To process the gradients, the volume of the PBS layer and the low concentration percoll layer were rapidly aspirated. A band of microglia (usually 0.5–1.5mL), captured between the low concentration and high concentration percoll layers was then collected and diluted in 50mL of 1× PBS. This was centrifuged at  $1000 \times g$  for 10min at full acceleration and brake. The supernatant was quickly decanted and the cell pellet resuspended in DMEM culture media containing 10% FBS. We also added 0.15µg/mL granulocyte monocyte colony stimulating factor (GM-CSF, R & D Systems, Minneapolis, MN), although this is not required for culturing microglia.

#### 2.5. Immunocytochemistry

Isolated cells were grown in culture media overnight. Cells were then washed, fixed in 4% paraformaldehyde and processed for immunofluorescence of microglial antigen Iba1 (1:500, Wako, Richmond, VA), microglial antigen Cd11b (1:1000, Serotec, Raleigh, NC), astrocyte antigen GFAP (1:1000, Dako Corporation, Carpinteria, CA), and neuronal antigen NeuN (1:500, Millipore, Billerica, MA). Cells were rinsed and incubated with goat anti-rabbit Alexa 488 (Invitrogen, Carlsbad, CA) and goat anti-mouse Alexa 568 (Invitrogen, Carlsbad, CA). For dendritic cell control experiments, cells were fixed in acetone and blocked for endogenous avidin/biotin (Vector: Burlingame, CA) and stained with dendritic cell antigen Cd11c (Pharmingen, San Diego, CA) and biotin mouse anti-hamster (Pharmingen, San Diego, CA). Normal mouse spleen sections were utilized as a positive

control. Cells were photographed with an Olympus DP71 camera mounted on an Olympus BX60 microscope.

## 2.6. Cell viability

Microglial mitochondrial respiratory activity, a measure of cell viability, was determined using a colorimetric MTT (methylthiazolyldiphenyl-tetrazolium bromide) assay (Bioassay Systems, Hayward, CA). This was compared to a reference value of HEK-293 cells, a highly viable immortal cell line, and dying cultures treated with 1% Triton X-100, a toxic reagent.

## 2.7. Microglial stimulation

In order to compare the inflammatory reaction of microglia in young and aged brains, cells were isolated from 2 and 14 months old mice, as described above, and seeded in 96-well tissue culture plates (Corning Incorporated, Corning, NY) at a density of  $3 \times 10^5$  cells/well. The cultures were incubated overnight at 37°C with 5% CO<sub>2</sub> and saturated humidity. The next day, cells were stimulated by replacing the original culture media with media containing 2% FBS and immunostimulatory agents in different concentrations. Two highly potent immune stimuli were selected, i.e. lipopolysaccharide (LPS, (*Escherichia coli* 055:B5) (Sigma, St. Louis, MO), a toll-like receptor 4 (TLR4) agonist and PamCSK3 (Invitrogen, Carlsbad, CA), a TLR2 agonist. LPS and PamCSK3 were added at a concentration of 10–100ng/mL (LPS) or 0.1–1µg/mL (PamCSK3). Control conditions were included, containing no stimuli. After 24hrs of incubation, the media of stimulated microglia were collected and centrifuged for 10min at 20°C and 1200rpm. The supernatants were used for IL-6 and TNF-α enzyme-linked immunosorbent assays (ELISA). For every condition, cytokine levels were calculated in three different wells, while each experiment was performed in quadruplicate.

## 2.8. IL-6 ELISA

Mouse IL-6 secreted protein levels were determined with a general sandwich ELISA protocol. Briefly, an enhanced protein binding ELISA plate (Nunc, Rochester, NY) was incubated overnight at 4°C with the capture antibody, rat anti-mouse IL-6 (BD Bioscience Erembodegem, Belgium). After blocking the non-specific binding for 2hrs, standards (BD Bioscience Erembodegem, Belgium) and samples were added for 2hrs at room temperature. Subsequently, biotinylated rat anti-mouse IL-6 (BD Bioscience Erembodegem, Belgium) was used as a detection antibody. Following incubation with a Streptavidin-Horseradish Peroxidase conjugate (Dako Cytomation, Heverlee, Belgium), a TMB substrate (BD Bioscience Erembodegem, Belgium) was applied to the plate. Finally, optical densities (OD) were read between 450–570nm, using a spectrophotometer (Powerwave X Select) and concentrations were calculated. The detection limit of the assay was 10pg/mL.

## 2.9. TNF-α ELISA

Mouse TNF-α secreted protein levels were measured using a commercially available ELISA kit (eBioscience, San Diego, CA), according to the manufacturer's instructions. Concentrations were determined according to the OD values, measured using a

spectrophotometer (Powerwave X Select) at a wavelength between 450–570nm. The detection limit of the assay was 8pg/mL.

## 2.10. Glutathione measurements

Total glutathione (reduced and oxidized) was measured in microglia using a glutathione reductase enzymatic recycling assay (Cayman Chemical, Ann Arbor, MI) that is based on the colorimetric conversion of nitrobenzoic acid to 5-thio-2-nitrobenzoic acid (Tietze, 1969). Briefly, microglia from the brains of young or aged mice were lysed immediately following isolation and prepared for glutathione measurements according to manufacturer's instructions. Glutathione levels within the range of standards were attained by combining microglia from four brains. Therefore to attain three repetitions, 12 mice per age group were assayed. All samples were normalized to total protein using bicinchonic acid (BCA) colorimetric assay (Pierce, Rockford, IL).

## 2.11. A $\beta$ 42 fate analysis

A $\beta$ 42 lyophilized protein with and without a FITC conjugate (rPeptide, Bogard, GA) was resuspended to 1mg/mL in 1% NH<sub>4</sub>OH and stored at –20°C according to manufacturer's directions. To visualize internalized amyloid beta in living cells, A $\beta$ 42-FITC was diluted to 4 $\mu$ g/mL in DMEM and added to microglia for 3hrs. The cells were then stained with DAPI nuclear counterstain (1:1000) for 5min. and imaged. For enhanced subcellular resolution of internalized amyloid beta, cells (exposed to non-conjugated A $\beta$ 42) were fixed as described above for immunocytochemistry using antibodies against amyloid beta (6E10, 1:2000, Signet Laboratories, Dedham, MA) and the lysosome associated protein, Lamp 1 (1:2, gift from Dr. Notterpek, University of Florida). To determine the aggregation state of A $\beta$ 42 in stock solutions used in internalization and fate experiments, samples were diluted in Laemmli sample buffer containing 2% sodium dodecyl sulfate (SDS) and loaded in 4–20% TG-SDS gels (Invitrogen, Carlsbad, CA) for standard SDS-PAGE. Immunoblots were probed with 6E10 at a dilution of 1:5000. 6E10 has affinity to individual A $\beta$ 42 peptides and therefore monomers, oligomers and higher order multimers of A $\beta$ 42 are distinguishable by size difference. Gel blots were photographed using a Fugifilm Life Science, Stamford, CT).

RS chambers (Nunc, Roskilde, Denmark) that contain a hybrid of glass and polystyrene surfaces have reduced non-specific interaction with A $\beta$  and were therefore chosen for fate analysis experimentation. To further reduce non-specific A $\beta$ 42 absorption, these chambers were blocked with 10% milk for 1hr. Microglial cells were then isolated from 1 month old mice, 15 months old mice and mixed glial cultures (MGC) were seeded on RS chambers at approximately  $3 \times 10^5$  cells/chamber. The cultures were incubated overnight at 37°C with 5% CO<sub>2</sub> and saturated humidity. The next day, cultures were rinsed and exposed to A $\beta$ 42 diluted in DMEM with 10% FBS at 4 $\mu$ g/mL. The cells were allowed to internalize A $\beta$ 42 from the media for 3hrs in 37°C (1.5ml/well). They were rinsed and incubated at 37°C with 1.5mLs of culture media lacking A $\beta$ 42. This media and that of cells lysed immediately following rinsing were collected, as were the conditioned media and lysate from wells incubated for 3hrs and 16hrs. The lysis buffer (1.5ml/well) consisted of NP40 (Invitrogen, Carlsbad, CA) supplemented with protease inhibitor cocktail (1 $\times$ , Sigma, St. Louis, MO)

and PMSF (1mM). For each age group, lysate and media representing 5–7 adult mice or 14 neonatal pups (2 MGCs) were collected. To determine the fate of A $\beta$ 42, we employed a sandwich-style ELISA (Invitrogen, Carlsbad, CA), configured with two capture antibodies (recognizing epitopes on the N terminus and C terminus of human A $\beta$ 42) to first capture the N terminus of A $\beta$ 42 and then the C terminus (Schmidt, et al., 2005). Microglial degradative activity on A $\beta$ 42 causes N terminal truncations (Majumdar, et al., 2007), thus ELISA reactivity is limited to non-degraded A $\beta$ 42. We were therefore able to 1) follow the loss of A $\beta$ 42 and 2) the expulsion of A $\beta$ 42 from microglia. The ELISA was processed with duplicates of each sample and absorbance read at 450nm using a spectrophotometer (Bio-Tek, Winooski, VT). The detection limit of the assay was 10pg/mL.

## 2.12. Statistical analysis

Average cytokine data are presented as mean  $\pm$  SEM. Statistical analysis was carried out using SPSS ver. 14.0 for Windows (SPSS, Chicago, IL). To analyze differences between groups, we used unpaired, two-tailed Student's t-test or ANOVA with a post hoc Bonferroni's test when appropriate. A p-value of  $<0.05$  was considered statistically significant. Average A $\beta$  data are presented as mean  $\pm$  SEM. For statistical comparison of A $\beta$  internalization between age groups, we used unpaired, two-tailed Student's t-test. For statistical comparison of A $\beta$  fate, paired, two-tailed Student's t-test was used to compare A $\beta$  levels immediately following internalization and 16hrs later. Data was normalized to mock-treated wells that were treated as described above but contained no cells. For comparison to mock-treated wells, raw data was used. A p-value of  $<0.05$  was considered statistically significant.

## 3. Results

As reported previously (de Haas, et al., 2007, Frank, et al., 2006), centrifugation of dissociated whole brain within discontinuous percoll gradients can separate microglia from other brain cells. In our hands, the techniques described in the literature yielded insufficiently pure cultures for the pulse-chase experiments we performed (Fig 1B–C). Specifically, we observed debris fields which limited the adherence of microglia and may contain components that possibly sequester amyloid beta peptide (Li, et al., 2005). To address this, we utilized dispase II, an enzyme that has been described as particularly gentle, yet capable of tissue dissociation (Borchelt, et al., 1992, Gao, et al., 2004, McDermott, et al., 2003). Furthermore, we increased the density of percoll by 16% from that described in the literature (de Haas, et al., 2007). We observed that brains treated with this methodology, i) had greater separation of dissociated microglia from tissue chunks (Fig 1A–B), ii) yielded numerous adherent microglia, and iii) were largely devoid of debris (Fig 1C–D).

Altogether, the combination of these techniques resulted in the extraction of up to  $3 \times 10^6$  microglia per brain. On average,  $8.5 \times 10^5$  microglia per brain were extracted from young and aged mice (Fig 2B). 94% of DAPI counterstained cells were reactive to Iba1 (Fig 2A) as determined by 3 observers. The cells had a characteristic amoeboid, phase bright morphology similar to previous reports of adult microglia (Tham, et al., 2003). To further confirm that our isolated cells were indeed microglia, we isolated cells from transgenic mice



where GFP expression is under the fractalkine receptor promoter. These mice are reported to have microglia as the only brain cell type to express GFP (Jung, et al., 2000). Upon isolation of cells, our cultures were reactive to antibodies specific to GFP (Supp Fig S3A). *Ex vivo* cultures of adult microglia that were allowed to adhere overnight were comparable to the HEK 293 cell line in viability (Fig 2C). Recent studies have raised the possibility that GM-CSF could push cultured microglia towards a dendritic cell fate (Esen and Kielian, 2007). In our cultures, microglia grown in 0.15 $\mu$ g/ml GM-CSF or in GM-CSF free conditions both maintained a rounded morphology (Supp Fig S4A) and had no immunoreactivity to the dendritic cell antigen, Cd11c (Supp Fig S4B, C). Interestingly, neonatal microglia derived from mixed glial cultures lacking GM-CSF exhibited a ramified phenotype when cultured overnight in GM-CSF containing media (Supp Fig S2). This morphology is similar to that observed in mixed glial cultures with prolonged exposure to GM-CSF (Esen and Kielian, 2007). It is possible that the conditions within mixed glial cultures prime microglia to adopt a dendritic-like morphological phenotype upon exposure to GM-CSF.

Previously, histological findings of dystrophic microglia in the aged and diseased brain have led our laboratory to suggest that microglial function may deteriorate with normal aging. Therefore, we sought to study elements of pathology that are mainly conferred by microglia *in vivo* and are known to change with aging and disease (Bolmont, et al., 2008, El Khoury, et al., 2007, Meyer-Luehmann, et al., 2008, Streit, et al., 2004, Ye and Johnson, 1999). Recent studies have shown that mRNA copies of inflammatory cytokines are increased in microglia from aged brains (Sierra, et al., 2007, Ye and Johnson, 1999). However, mRNA transcripts may not necessarily translate to secreted protein levels (Munger, et al., 1995, Storm van's Gravesande, et al., 2002), a more ultimate measure of functional change. To determine if microglia vary their secretion of cytokines with age, we obtained microglia from young and aged mice and measured their cytokine levels with and without exogenous immune stimulation.

The most striking observation in this respect was the dramatic increase in IL-6 release under basal conditions (young: 211.8 $\pm$ 31.7 pg/ml vs. aged: 3735.9 $\pm$ 1000.2 pg/ml,  $p < 0.001$ ). In both young and aged microglia, a significant dose-effect relation following either LPS or PAMCSK3 stimulation was observed (Supp Fig S5A). Moreover, maximal release of IL-6 was significantly enhanced in aged microglial cells following LPS (100ng/ml) or PAMCSK3 (1 $\mu$ g/ml) stimulation (Fig 3A).

As with IL-6, the amount of TNF- $\alpha$  produced by aged microglial cells was significantly higher under basal conditions when compared to young microglia. While microglia derived from young mice produced no TNF- $\alpha$  under basal conditions, the amount was significantly increased to 917.2  $\pm$  91.9 pg/ml in supernatants of aged microglia cultured for 24h without any exogenous stimuli ( $p < 0.001$ ). This striking difference confirms age-related higher basal levels of cytokine production previously observed with mRNA transcript analysis (Sierra, et al., 2007) and shows that aged microglia produce more TNF- $\alpha$  than microglia from young mice. This high release under basal conditions may explain the lack of a significant dose-effect relation in TNF- $\alpha$  production following either LPS or PAMCSK3 stimulation (Supp. Fig S5B). In contrast, in young microglia a significant dose-effect relation was observed. Moreover, although the maximal amount of TNF- $\alpha$  released by aged microglia in response

to 1µg/ml PAMCSK3 was slightly though significantly increased, responses to 100ng/ml LPS were not different between aged or young microglia (Fig 3B).

In addition to quantifying microglial cytokine production as a function of age, we were interested in whether the ability of microglia to serve as an oxidative sink and to internalize amyloid beta changes with age. Glutathione acts as antioxidant by neutralizing free radicals and peroxides and microglia are reported to be the primary glutathione containing cells in the brain (Hirrlinger, et al., 2000, Lindenau, et al., 1998). We found a trend indicating that microglia in aged brains have 21% less total glutathione (oxidized and reduced) compared to microglia from young brains (Supp Fig S6). This result suggests the reactive oxygen species (ROS) insult that can be caused by amyloid beta internalization (Milton, et al., 2008) maybe more injurious to microglia in aged brains.

Amyloid beta accumulation is a well recognized feature of AD, however, extensive amyloid deposits may be found in many aged, non-demented individuals (Bouras, et al., 1994). This pathology may result from AD-independent deterioration of clearance processes. Microglial scavenger activity on amyloid beta is proposed as a clearance process that contributes in maintaining amyloid beta at physiological levels by counterbalancing constitutive amyloid beta secretion by neurons. Our laboratory and others have published accounts of microglial degeneration associated with aging (Flanary, et al., 2007, Simmons, et al., 2007, Streit, et al., 2008, Streit, et al., 2004). If microglia represent a major amyloid beta clearance mechanism, their degeneration would result in progressively increasing amyloid beta levels with age and therefore would have significant implications to the occurrence of amyloidosis in AD and some aged individuals. We currently lack the means to isolate degenerating microglia for experimentation. However, *ex vivo* assessment of microglia isolated acutely from young and aged mice likely emulates *in vivo* processing of amyloid beta more so than neonatal or 'microglial-like' cell lines and may give insight to the degeneration of microglia with age. *Ex vivo* cultures of microglia were given media with 4µg/mL of Aβ42-FITC conjugate or non-conjugated Aβ42. Western blot analysis indicated that non-conjugated Aβ42 preparations contained Aβ42 monomers, oligomers and SDS resistant species larger than 220kDa that are likely fibrils thus reflecting *in vivo* amyloid burden (Fig 4A). Internalization of Aβ42 by living microglia was confirmed visually with cell-associated FITC fluorescence (Fig 4B). Aβ42 observed in fixed cells was colocalized with lysosomes (Fig 4C).

To quantify internalization, microglial lysates were measured using an Aβ42 sensitive ELISA. Our results indicate that microglia from aged (15 month old) mice internalize 0.279ng/ml of Aβ42 (Fig 5A). In similar experiments recently performed by Zaghi et al., monocytes from aged humans (mean age:77years) are reported to internalize 0.256 ng/ml of Aβ42, a value within 8% of our findings in aged mouse microglia (Zaghi, et al., 2009). Because circulating monocytes are under certain conditions able to infiltrate the parenchyma, differentiate into microglia (Mildner, et al., 2007, Simard and Rivest, 2004) and modify amyloidosis (Simard, et al., 2006), the similarity of our measurements to human monocyte measurements indicates a strong possibility that our experiments model human physiology.



To determine whether A $\beta$ 42 processing by microglia from younger mice is reflective of microglia from aged mice, we next performed experiments with microglia from neonates (< 8 days old, mixed glial culture derived) and young (1 month old) mice (Supp Fig. S1). We found that young microglia internalized 53% more A $\beta$ 42 relative to aged microglia, while neonatal microglia internalized 45% more A $\beta$ 42 than young microglia (Fig 5A). Neonatal microglia internalized 74% more A $\beta$ 42 than aged microglia. This suggests that the neonatal microglia commonly used for research on Alzheimer's disease and aging, may not necessarily model adult microglial A $\beta$ 42 clearance activity.

Internalization of A $\beta$ 42 is a prerequisite step for intracellular clearance; however it is by no means a surrogate marker for biophysical A $\beta$ 42 degradation. To more comprehensively determine the fate of phagocytosed A $\beta$ 42, we bathed cells in fresh media and measured the levels of A $\beta$ 42 in this media and within cells over 16hrs. We observed that internalized A $\beta$ 42 is invariably expelled by younger microglial cells within 3hrs (Fig 5B). The amount of A $\beta$ 42 that was expelled by neonatal microglia stayed nearly constant after 3hrs and averages to 18% less than what was originally internalized. This result may mean neonatal microglia were able to degrade some internalized A $\beta$ 42. Young microglia appeared to continuously expel A $\beta$ 42 (41% increase between 3hrs and 16hrs). At 16hrs, young microglia expelled 27% more A $\beta$ 42 than neonatal microglia. We did not see significant evidence of A $\beta$ 42 expulsion by aged microglia though these microglia have reduced amounts of internalized A $\beta$ 42 over time. The amount of A $\beta$ 42 internalized by aged microglia is not significantly different from mock experiments. Therefore, we were unable to assess whether these cells have degradation capacities.

Interestingly, the amount of A $\beta$ 42 expelled by young microglia at 3hrs and 16hrs was 19% and 53% more than was initially internalized. In mock measurements performed alongside neonatal and young microglial experiments, we found that A $\beta$ 42 capture is enhanced by 31% in the media compared to lysis buffer. Lysates are composed of a complex mixture that includes chemicals for lysis, protease inhibitors, cell-derived proteins as well as lipids. These are not found in the media. Because a more limited set of soluble proteins compete for ELISA antibody binding in the media, one would expect enhanced capture of A $\beta$ 42 in this environment. Consequently, our assay does not yield stoichiometric data needed for affirmative determination of A $\beta$ 42 degradation. However our assay clearly detects significant increases in conditioned media A $\beta$ 42 content suggesting substantial movement of A $\beta$ 42 to the outside of cells following initial internalization. This effect is age-related as it is only observed in younger microglial cells.

#### 4. Discussion

In this report, we aimed to reduce debris contamination which is a feature of microglial cultures derived from gradient centrifugation based methodology. The brains of mice that are designated by the National Institute on Aging as an aging model were treated successively to steps that significantly increased the purity of *ex vivo* microglial cultures. Analysis of such cultures, derived from mice of various aging categories, revealed that microglia from aged brains have markedly increased basal levels of IL-6 and TNF- $\alpha$  secretion, have reduced glutathione levels and have a limited capacity to ingest A $\beta$ 42. In

contrast, microglia from younger mice are able to temporarily contain A $\beta$ 42. Together, these *ex vivo* findings provide evidence that microglia are subject to age-associated changes in biology.

Prior reports from our laboratory have shown that microglia have IL-6 and TNF- $\alpha$  mRNA (Streit, et al., 2000) and more recently, others have found age-related changes in microglial IL-6 and TNF- $\alpha$  mRNA (Sierra, et al., 2007). We extend on these results by measuring secreted IL-6 and TNF- $\alpha$  proteins. Our results indicate significantly more pronounced changes in basal cytokine production and responsiveness. It is difficult to make direct comparisons of mRNA and secreted protein measurements. However, it is of note that the margin of change we observe in the basal production of IL-6 between microglia from young and aged mice is approximately 4-fold higher than that observed by mRNA analysis (17.6 $\times$  vs. 5 $\times$  respectively). We also did not observe detectable levels of basal TNF- $\alpha$  by microglia from young animals in our studies. These differences can perhaps be explained by varying sensitivities of the employed detection methodologies or by post-transcriptional effects. The half-life of mRNA can often be rate-limiting in translation (Ross, 1995). Secondly, secretory pathway modulation of newly produced cytokines may also modulate the concentration of cytokines in the extracellular milieu independent of DNA transcription. As microRNAs are involved in regulation of gene expression at the post-transcriptional level, possible changes in this machinery can also be mentioned to explain the discrepancy between protein and mRNA levels. Our results, though in agreement with previous reports, indicate that microglia from brains of various aging groups have much greater differences in cytokine production, and responsiveness to immune stimulation than was previously thought.

What are the possible implications of age-related changes in microglial cytokine production? A number of authors commonly describe IL-6 and TNF- $\alpha$  as neurotoxic molecules involved in AD pathogenesis (Bruunsgaard, et al., 1999, Collins, et al., 2000, Culpan, et al., 2003, He, et al., 2002, Li, et al., 2007, Licastro, et al., 2000, McGeer and McGeer, 2001). However, experiments presenting alternative viewpoints have been published (Brunello, et al., 2000, Loddick, et al., 1998, Marz, et al., 1998, Streit, et al., 2000, Tarkowski, et al., 1999, Thier, et al., 1999, Wei, et al., 1992). IL-6 may have a role in regeneration of injured tissue in the brain (Loddick, et al., 1998, Streit, et al., 2000, Tarkowski, et al., 1999), has known anti-apoptotic properties (Wei, et al., 2001) and in mice that overexpress both IL-6 and its receptor, IL-6R $\alpha$ , there is no evidence of neurotoxicity (Brunello, et al., 2000). Inflammation is a component of the healing process of acute CNS lesions (Klein, et al., 1997, Streit, et al., 2000). Recently, it has been reported that the more chronic lesions of tauopathy and amyloidosis can be found in 20–40% of non-diseased, aged adults at levels comparable to AD patients (Price, et al., 2009). Both TNF- $\alpha$  and IL-6 increase with aging (Bruunsgaard, et al., 1999, Wei, et al., 1992). Thus, the aging brain appears to exist in a constant state of injury. Inflammatory processes, such as microglial secretion of IL-6, maybe needed for persistent regeneration or neuroprotection. The viewpoints that cytokine release is exclusively neurotoxic or neuroprotective could be equally considered speculative. Further studies which consider region-specific and age-specific differences in cytokine

response are needed, amongst others, to shed light onto the role of cytokines released by microglia on the nervous system.

Microglial surveillance of the parenchyma involves scavenging of potentially hazardous materials. Proteins such as LPS and A $\beta$  induce ROS and it is thought that the increased levels of antioxidant molecules such as glutathione found in microglia relative to other brain cells (Hirrlinger, et al., 2000, Lindenau, et al., 1998) protect microglia from ROS burden associated with scavenging activity (Dringen, 2005, Milton, et al., 2008, Qin, et al., 2004, Tchaikovskaya, et al., 2005). Our findings of reduced glutathione levels in microglia immediately analyzed after brain extraction may be indicative of broader microglial loss of function with age.

Our overall conclusion of age-related changes in microglial processing of A $\beta$  is indirectly supported by published work demonstrating decreased protein turnover in adult rat microglia (Stolzing, et al., 2006). More recently, experiments by Zahgi et al. show monocytes from aged humans internalized A $\beta$ 42 at amounts comparable to what we observe in aged mouse microglia (Zaghi, et al., 2009). Similar to our findings, the A $\beta$  internalized by monocytes was not detected in cell lysates within hours. In other work, media was measured for radio labeled soluble A $\beta$  previously internalized by neonatal microglia. These investigators concluded that most A $\beta$  is expelled in an interval of time similar to our findings (Chung, et al., 1999). Together, these data provide independent support for the amount of A $\beta$  we measure in lysates, the kinetics of A $\beta$  movement, and our conclusion that the principal consequence of A $\beta$  internalization by younger microglia is expulsion.

Microglia are thought to participate in plaque burden regulation by sequestering and processing of A $\beta$ . Our purpose in performing A $\beta$  metabolism experiments with *ex vivo* cultures of microglia was to further understand the relationship between microglia and A $\beta$ 42 homeostasis. Individual microglia surrounding A $\beta$  plaques become enlarged as plaques become smaller with time (Bolmont, et al., 2008). Despite this correlative evidence of microglial participation in A $\beta$  plaque reduction, natural processes do not appear to reverse amyloidosis (Jankowsky, et al., 2005). Previously, we have suggested that microglial function may deteriorate with time. This was mainly inspired by histological findings, demonstrating the appearance of a dystrophic microglia phenotype with normal aging and around neuritic plaques in AD brains (Streit, et al., 2009). The finding that microglia from young brains internalize more A $\beta$ 42 than microglia from aged brains likely reflects a more global change in microglial functionality with aging.

In younger mice, the temporary sequestration of A $\beta$ 42 suggests that microglia are not directly involved in significant amounts of degradation. However there is clear potential for microglia, which are highly motile (Bolmont, et al., 2008), to be involved in the movement of A $\beta$  in the nervous system. The cycling of A $\beta$ 42 through microglial endocytosis and exocytosis could result in redistribution that modulates peptide availability for amyloid formation. Our observations indicate that microglia remove A $\beta$  peptide out of the extracellular milieu at ng/ml quantities, possibly creating a dynamic cellular compartment *in vivo*. A 2- to 4-fold age-related decrease in microglial A $\beta$  internalization as observed in our experiments could result in less transfer of A $\beta$  from the extracellular space, thereby making

available more A $\beta$  for plaque formation. It is plausible that the dynamic redistribution of A $\beta$ , a protein that is particularly aggregation prone, is needed for homeostatic maintenance. Perturbation of this process due to age-related changes of microglial function such as that described here could contribute to unhinged accumulation of A $\beta$  to toxic concentrations in the extracellular space. In 3 month old mice where *in vivo* microglia were selectively killed, soluble A $\beta$ 40 and A $\beta$ 42 levels increase by 3–4 fold (Grathwohl, et al., 2009). This suggests that the presence of microglia is needed to prevent the accumulation of soluble pools of A $\beta$  in young mice. Such pools contain the building blocks of A $\beta$  pathology according to the amyloid cascade theory (Tanzi and Bertram, 2005). Interestingly, amyloidosis has recently been described to occur in up to 40% of non-demented, aged adults (Price, et al., 2009). It is possible that changes in microglial processing of A $\beta$  may contribute to occurrences of amyloidosis in the aged population. Suggestive evidence for this comes from studies of monocytes. In these studies, monocytes from Alzheimer's patients internalize half as much A $\beta$ 42 as those from aged adults (Zaghi, et al., 2009). Importantly, aged monocytes have a similar capacity to internalize A $\beta$ 42 as aged mouse microglia measured here. We infer from our data that monocytes and microglia from younger humans will have greater internalization of A $\beta$ 42. We propose that as microglia and possibly monocytes age, they lose important capacities to internalize and redistribute A $\beta$ . A progressive loss of cellular function as described here may be an understudied mechanism that contributes to the development of amyloid pathology in aged, non-demented subjects and in patients with Alzheimer's disease.

Together, our *ex vivo* quantification of microglial functions of cytokine production, glutathione levels and A $\beta$ 42 scavenging activity paint a complex picture of endogenous activity. Microglia from young mice produce less cytokines, while microglia derived from aged mice have higher basal levels of cytokine secretion than was previously thought and have reduced glutathione levels. Microglia derived from aged mice have diminished A $\beta$ 42 internalization capacity relative to their younger counterparts. However, these younger microglia expel significant amounts of internalized A $\beta$ 42. These direct assessments of microglial function in *ex vivo* experiments, free of confounding contributions of other brain cells and debris, demonstrate a nuanced view of microglial function and suggest that microglial biology may change with aging.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

This study was supported by: (1) the NIH Neurobiology of Aging NRSA Training Grant T32 AG000196-16A1 (2) ROI-NS042775, ROI-AG023665, (3) SantaFe HealthCare Alzheimer's Disease Research Center, and (4) a pilot (07552) and a travel grant of the "Internationale Stichting Alzheimer Onderzoek (ISAO)."

## References

- Boillee S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, Kollias G, Cleveland DW. Onset and progression in inherited ALS determined by motor neurons and microglia. *Science*. 2006; 312(5778):1389–1392. [PubMed: 16741123]


- Bolmont T, Haiss F, Eicke D, Radde R, Mathis CA, Klunk WE, Kohsaka S, Jucker M, Calhoun ME. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. *J Neurosci*. 2008; 28(16):4283–4292. [PubMed: 18417708]
- Borchelt DR, Taraboulos A, Prusiner SB. Evidence for synthesis of scrapie prion proteins in the endocytic pathway. *J Biol Chem*. 1992; 267(23):16188–16199. [PubMed: 1353761]
- Bouras C, Hof PR, Giannakopoulos P, Michel JP, Morrison JH. Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital. *Cereb Cortex*. 1994; 4(2): 138–150. [PubMed: 8038565]
- Brunello AG, Weissenberger J, Kappeler A, Vallan C, Peters M, Rose-John S, Weis J. Astrocytic alterations in interleukin-6/Soluble interleukin-6 receptor alpha double-transgenic mice. *Am J Pathol*. 2000; 157(5):1485–1493. [PubMed: 11073809]
- Bruunsgaard H, Andersen-Ranberg K, Jeune B, Pedersen AN, Skinhoj P, Pedersen BK. A high plasma concentration of TNF-alpha is associated with dementia in centenarians. *J Gerontol A Biol Sci Med Sci*. 1999; 54(7):M357–M364. [PubMed: 10462168]
- Carson MJ, Reilly CR, Sutcliffe JG, Lo D. Mature microglia resemble immature antigen-presenting cells. *Glia*. 1998; 22(1):72–85. [PubMed: 9436789]
- Chung H, Brazil MI, Irizarry MC, Hyman BT, Maxfield FR. Uptake of fibrillar beta-amyloid by microglia isolated from MSR-A (type I and type II) knockout mice. *Neuroreport*. 2001; 12(6):1151–1154. [PubMed: 11338182]
- Chung H, Brazil MI, Soe TT, Maxfield FR. Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid beta-peptide by microglial cells. *J Biol Chem*. 1999; 274(45):32301–32308. [PubMed: 10542270]
- Collins JS, Perry RT, Watson B Jr, Harrell LE, Acton RT, Blacker D, Albert MS, Tanzi RE, Bassett SS, McInnis MG, Campbell RD, Go RC. Association of a haplotype for tumor necrosis factor in siblings with late-onset Alzheimer disease: the NIMH Alzheimer Disease Genetics Initiative. *Am J Med Genet*. 2000; 96(6):823–830. [PubMed: 11121190]
- Culpan D, MacGowan SH, Ford JM, Nicoll JA, Griffin WS, Dewar D, Cairns NJ, Hughes A, Kehoe PG, Wilcock GK. Tumour necrosis factor-alpha gene polymorphisms and Alzheimer's disease. *Neurosci Lett*. 2003; 350(1):61–65. [PubMed: 12962917]
- de Haas AH, Boddeke HW, Brouwer N, Biber K. Optimized isolation enables ex vivo analysis of microglia from various central nervous system regions. *Glia*. 2007; 55(13):1374–1384. [PubMed: 17661344]
- Dringen R. Oxidative and antioxidative potential of brain microglial cells. *Antioxid Redox Signal*. 2005; 7(9–10):1223–1233. [PubMed: 16115027]
- El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, Luster AD. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. *Nat Med*. 2007; 13(4):432–438. [PubMed: 17351623]
- Esen N, Kielian T. Effects of low dose GM-CSF on microglial inflammatory profiles to diverse pathogen-associated molecular patterns (PAMPs). *J Neuroinflammation*. 2007; 4:10. [PubMed: 17374157]
- Flanary BE, Sammons NW, Nguyen C, Walker D, Streit WJ. Evidence that aging and amyloid promote microglial cell senescence. *Rejuvenation Res*. 2007; 10(1):61–74. [PubMed: 17378753]
- Frank MG, Wieseler-Frank JL, Watkins LR, Maier SF. Rapid isolation of highly enriched and quiescent microglia from adult rat hippocampus: immunophenotypic and functional characteristics. *J Neurosci Methods*. 2006; 151(2):121–130. [PubMed: 16125247]
- Frautschy SA, Yang F, Irizarry M, Hyman B, Saido TC, Hsiao K, Cole GM. Microglial response to amyloid plaques in APPsw transgenic mice. *Am J Pathol*. 1998; 152(1):307–317. [PubMed: 9422548]
- Gao CY, Stepp MA, Fariss R, Zelenka P. Cdk5 regulates activation and localization of Src during corneal epithelial wound closure. *J Cell Sci*. 2004; 117(Pt 18):4089–4098. [PubMed: 15280426]
- Grathwohl SA, Kalin RE, Bolmont T, Prokop S, Winkelmann G, Kaeser SA, Odenthal J, Radde R, Eldh T, Gandy S, Aguzzi A, Staufenbiel M, Mathews PM, Wolburg H, Heppner FL, Jucker M.

- Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia. *Nat Neurosci.* 2009; 12(11):1361–1363. [PubMed: 19838177]
- He BP, Wen W, Strong MJ. Activated microglia (BV-2) facilitation of TNF-alpha-mediated motor neuron death in vitro. *J Neuroimmunol.* 2002; 128(1–2):31–38. [PubMed: 12098508]
- Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. *J Neurosci.* 2008; 28(33):8354–8360. [PubMed: 18701698]
- Hirrlinger J, Gutterer JM, Kussmaul L, Hamprecht B, Dringen R. Microglial cells in culture express a prominent glutathione system for the defense against reactive oxygen species. *Dev Neurosci.* 2000; 22(5–6):384–392. [PubMed: 11111154]
- Jankowsky JL, Slunt HH, Gonzales V, Savonenko AV, Wen JC, Jenkins NA, Copeland NG, Younkin LH, Lester HA, Younkin SG, Borchelt DR. Persistent amyloidosis following suppression of Aβeta production in a transgenic model of Alzheimer disease. *PLoS Med.* 2005; 2(12):e355. [PubMed: 16279840]
- Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, Littman DR. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. *Mol Cell Biol.* 2000; 20(11):4106–4114. [PubMed: 10805752]
- Klein MA, Moller JC, Jones LL, Bluethmann H, Kreutzberg GW, Raivich G. Impaired neuroglial activation in interleukin-6 deficient mice. *Glia.* 1997; 19(3):227–233. [PubMed: 9063729]
- Li JP, Galvis ML, Gong F, Zhang X, Zcharia E, Metzger S, Vlodavsky I, Kisilevsky R, Lindahl U. In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis. *Proc Natl Acad Sci U S A.* 2005; 102(18):6473–6477. [PubMed: 15843464]
- Li L, Lu J, Tay SS, Mochhala SM, He BP. The function of microglia, either neuroprotection or neurotoxicity, is determined by the equilibrium among factors released from activated microglia in vitro. *Brain Res.* 2007; 1159:8–17. [PubMed: 17572395]
- Licastro F, Pedrini S, Caputo L, Annoni G, Davis LJ, Ferri C, Casadei V, Grimaldi LM. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? *J Neuroimmunol.* 2000; 103(1):97–102. [PubMed: 10674995]
- Lindenau J, Noack H, Asayama K, Wolf G. Enhanced cellular glutathione peroxidase immunoreactivity in activated astrocytes and in microglia during excitotoxin induced neurodegeneration. *Glia.* 1998; 24(2):252–256. [PubMed: 9728771]
- Loddick SA, Turnbull AV, Rothwell NJ. Cerebral interleukin-6 is neuroprotective during permanent focal cerebral ischemia in the rat. *J Cereb Blood Flow Metab.* 1998; 18(2):176–179. [PubMed: 9469160]
- Majumdar A, Cruz D, Asamoah N, Buxbaum A, Sohar I, Lobel P, Maxfield FR. Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils. *Mol Biol Cell.* 2007; 18(4):1490–1496. [PubMed: 17314396]
- Marz P, Cheng JG, Gadiant RA, Patterson PH, Stoyan T, Otten U, Rose-John S. Sympathetic neurons can produce and respond to interleukin 6. *Proc Natl Acad Sci U S A.* 1998; 95(6):3251–3256. [PubMed: 9501249]
- McDermott JR, Bartram RE, Knight PA, Miller HR, Garrod DR, Grecis RK. Mast cells disrupt epithelial barrier function during enteric nematode infection. *Proc Natl Acad Sci U S A.* 2003; 100(13):7761–7766. [PubMed: 12796512]
- McGeer PL, McGeer EG. Polymorphisms in inflammatory genes and the risk of Alzheimer disease. *Arch Neurol.* 2001; 58(11):1790–1792. [PubMed: 11708985]
- Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsnecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. *Nature.* 2008; 451(7179):720–724. [PubMed: 18256671]
- Mildner A, Schmidt H, Nitsche M, Merkler D, Hanisch UK, Mack M, Heikenwalder M, Bruck W, Priller J, Prinz M. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. *Nat Neurosci.* 2007; 10(12):1544–1553. [PubMed: 18026096]



- Milton RH, Abeti R, Averaimo S, DeBiasi S, Vitellaro L, Jiang L, Curmi PM, Breit SN, Duchon MR, Mazzanti M. CLIC1 function is required for beta-amyloid-induced generation of reactive oxygen species by microglia. *J Neurosci*. 2008; 28(45):11488–11499. [PubMed: 18987185]
- Munger JS, Haass C, Lemere CA, Shi GP, Wong WS, Teplow DB, Selkoe DJ, Chapman HA. Lysosomal processing of amyloid precursor protein to A beta peptides: a distinct role for cathepsin S. *Biochem J*. 1995; 311(Pt 1):299–305. [PubMed: 7575468]
- Ponomarev ED, Novikova M, Maresz K, Shriver LP, Dittel BN. Development of a culture system that supports adult microglial cell proliferation and maintenance in the resting state. *J Immunol Methods*. 2005; 300(1–2):32–46. [PubMed: 15893321]
- Price JL, McKeel DW Jr, Buckles VD, Roe CM, Xiong C, Grundman M, Hansen LA, Petersen RC, Parisi JE, Dickson DW, Smith CD, Davis DG, Schmitt FA, Markesbery WR, Kaye J, Kurlan R, Hulette C, Kurland BF, Higdon R, Kukull W, Morris JC. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. *Neurobiol Aging*. 2009; 30(7):1026–1036. [PubMed: 19376612]
- Qin L, Liu Y, Wang T, Wei SJ, Block ML, Wilson B, Liu B, Hong JS. NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. *J Biol Chem*. 2004; 279(2):1415–1421. [PubMed: 14578353]
- Rogers J, Strohmeyer R, Kovelowski CJ, Li R. Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide. *Glia*. 2002; 40(2):260–269. [PubMed: 12379913]
- Ross J. mRNA stability in mammalian cells. *Microbiol Rev*. 1995; 59(3):423–450. [PubMed: 7565413]
- Schmidt SD, Nixon RA, Mathews PM. ELISA method for measurement of amyloid-beta levels. *Methods Mol Biol*. 2005; 299:279–297. [PubMed: 15980612]
- Sierra A, Gottfried-Blackmore AC, McEwen BS, Bulloch K. Microglia derived from aging mice exhibit an altered inflammatory profile. *Glia*. 2007; 55(4):412–424. [PubMed: 17203473]
- Simard AR, Rivest S. Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia. *FASEB J*. 2004; 18(9):998–1000. [PubMed: 15084516]
- Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. *Neuron*. 2006; 49(4):489–502. [PubMed: 16476660]
- Simmons DA, Casale M, Alcon B, Pham N, Narayan N, Lynch G. Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease. *Glia*. 2007; 55(10):1074–1084. [PubMed: 17551926]
- Stolzing A, Widmer R, Jung T, Voss P, Grune T. Tocopherol-mediated modulation of age-related changes in microglial cells: turnover of extracellular oxidized protein material. *Free Radic Biol Med*. 2006; 40(12):2126–2135. [PubMed: 16785026]
- Storm van's Gravesande K, Layne MD, Ye Q, Le L, Baron RM, Perrella MA, Santambrogio L, Silverman ES, Riese RJ. IFN regulatory factor-1 regulates IFN-gamma-dependent cathepsin S expression. *J Immunol*. 2002; 168(9):4488–4494. [PubMed: 11970993]
- Streit WJ, Braak H, Xue QS, Bechmann I. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. *Acta Neuropathol*. 2009; 118(4):475–485. [PubMed: 19513731]
- Streit WJ, Hurley SD, McGraw TS, Semple-Rowland SL. Comparative evaluation of cytokine profiles and reactive gliosis supports a critical role for interleukin-6 in neuron-glia signaling during regeneration. *J Neurosci Res*. 2000; 61(1):10–20. [PubMed: 10861795]
- Streit WJ, Miller KR, Lopes KO, Njie E. Microglial degeneration in the aging brain--bad news for neurons? *Front Biosci*. 2008; 13:3423–3438. [PubMed: 18508444]
- Streit WJ, Mrak RE, Griffin WS. Microglia and neuroinflammation: a pathological perspective. *J Neuroinflammation*. 2004; 1(1):14. [PubMed: 15285801]
- Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. *Cell*. 2005; 120(4):545–555. [PubMed: 15734686]


- Tarkowski E, Blennow K, Wallin A, Tarkowski A. Intracerebral production of tumor necrosis factor- $\alpha$ , a local neuroprotective agent, in Alzheimer disease and vascular dementia. *J Clin Immunol.* 1999; 19(4):223–230. [PubMed: 10471976]
- Tchaikovskaya T, Fraifeld V, Urphanishvili T, Andorfer JH, Davies P, Listowsky I. Glutathione S-transferase hGSTM3 and ageing-associated neurodegeneration: relationship to Alzheimer's disease. *Mech Ageing Dev.* 2005; 126(2):309–315. [PubMed: 15621212]
- Tham CS, Lin FF, Rao TS, Yu N, Webb M. Microglial activation state and lysophospholipid acid receptor expression. *Int J Dev Neurosci.* 2003; 21(8):431–443. [PubMed: 14659994]
- Thier M, Marz P, Otten U, Weis J, Rose-John S. Interleukin-6 (IL-6) and its soluble receptor support survival of sensory neurons. *J Neurosci Res.* 1999; 55(4):411–422. [PubMed: 10723052]
- Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. *Anal Biochem.* 1969; 27(3):502–522. [PubMed: 4388022]
- Wei J, Xu H, Davies JL, Hemmings GP. Increase of plasma IL-6 concentration with age in healthy subjects. *Life Sci.* 1992; 51(25):1953–1956. [PubMed: 1453878]
- Wei LH, Kuo ML, Chen CA, Chou CH, Cheng WF, Chang MC, Su JL, Hsieh CY. The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway. *Oncogene.* 2001; 20(41):5799–5809. [PubMed: 11593385]
- Ye SM, Johnson RW. Increased interleukin-6 expression by microglia from brain of aged mice. *J Neuroimmunol.* 1999; 93(1–2):139–148. [PubMed: 10378877]
- Zaghi J, Goldenson B, Inayathullah M, Lossinsky AS, Masoumi A, Avagyan H, Mahanian M, Bernas M, Weinand M, Rosenthal MJ, Espinosa-Jeffrey A, de Vellis J, Teplow DB, Fiala M. Alzheimer disease macrophages shuttle amyloid-beta from neurons to vessels, contributing to amyloid angiopathy. *Acta Neuropathol.* 2009; 117(2):111–124. [PubMed: 19139910]




**Fig. 1.**

Dispose II density centrifugation methodology: (A) Brain hemispheres that were homogenized with dispose II and loaded onto discontinuous gradients composed of 35% 'low' percoll and 75% 'high' percoll sequestered microglia to an isopycnic density of 1.077mg/μl as determined by beads with known densities. This configuration spatially separated unwanted brain matter to a density 50μg/μl more buoyant. (B) Density centrifugation methodology as described in the literature involved mechanical homogenization and reduced percoll densities. In our hands, such methodology failed to

channel unwanted brain matter (tissue chunks, red arrowhead) to an isopycnic position distal to the microglia enriched band. (C) Phase contrast images of freshly prepared cells under a hemacytometer demonstrate reduced particulate matter from dispase II homogenized brains and viable phase-bright cells that exclude trypan blue. Following 24hrs of culture, these cells remain adherent after multiple washes (D) and are thus compatible with experiments that involve media exchanges.


**Fig. 2.**

Purity, yield and viability of microglia: (A) Microglia isolated with dispase II density centrifugation methodology express Iba1, a marker commonly used to identify microglia *in vivo*. (B) Yields of microglia from 1 month old and 15 month old mice typically obtained using dispase II based density centrifugation methodology show little variability with age. (C) Measurement of mitochondrial respiratory activity indicated that isolated microglia form cultures comparable in viability to HEK 293 cells, an immortal cell line.


**Fig. 3.**

Cytokine secretion of young and aged microglia: (A) Upon stimulation with the biological immunostimulatory agent LPS (100ng/ml), or Pam3CSK4, a synthetic agonist of toll-like receptor 2 (1µg/ml), IL-6 production by aged microglia was markedly increased when compared to young microglia. (B) LPS (100ng/ml) stimulated similar TNF-α production in microglia derived from young and aged mice. Yet, TNF-α production was significantly increased in aged microglia following Pam3CSK4 (1µg/ml) exposure. \*,  $p < 0.05$ ; #,  $p < 0.001$ .



**Fig. 4.**

(A) Western blot analysis using 6E10, an antibody specific to the first 16 amino acids of Aβ42, indicates monomeric (4kDa), oligomeric (16kDa, 20kDa) and higher-order conformations larger than 220kDa in stock preparations as well as preparations that have been exposed to microglia. Higher-order conformations larger than 220kDa persist following the exposure of samples to buffer containing 2% SDS suggesting the presence of fibrillar species. 10% serum in media overloads gel at 60kDa and may block visibility of some Aβ42 species. 75ng Aβ42/well. (B) Internalization of Aβ42 by microglia from adult mice was directly observed in living microglia with FITC conjugated Aβ42 peptide and with 6E10 immunocytochemistry. In both cases, Aβ42 had a perinuclear localization. Lamp1 colocalization with 6E10 immunoreactivity suggests that some Aβ42 reached microglial lysosomal compartments (C).

**Fig. 5.**

Fate of A $\beta$  internalized by microglia: Microglia extracted from mice of various ages were exposed to A $\beta$ 42 preparations containing monomeric, oligomeric and SDS-resistant fibrillar species (reflecting *in vivo* amyloid diversity) in pulse-chase experiments. (A) Neonatal and young microglia respectively internalized 74% and 53% more A $\beta$ 42 relative to aged microglia. (B) Invariably, internalized A $\beta$ 42 was expelled by neonatal and young microglia within 3hrs of ingestion, suggesting disengagement from biophysical degradation following phagocytosis. Mock data (gray) represents experiments without the presence of cells to

control for non-specific adherence of A $\beta$  to culture wells. Detection of A $\beta$ 42 requires the presence of both NH<sub>2</sub> and COOH terminals of A $\beta$ 42, thus only intact A $\beta$ 42 peptides are quantified in the above experiments. \*, p<0.05; \*\*, p<0.01.